Semaglutide

Semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are injectable GLP-1 receptor agonist medications which is FDA approved for weight management and treating diabetes. The injections are typically administered once weekly, but timing of injections may differ depending on the patient. Dosing will vary, with lower dose to begin.

MAAA obtains its generic GLP-1 medications from a licensed registered pharmacy in the U.S. that is authorized to do compounding.

In addition to controlling diabetes and weight, the medications have also shown to be of benefit for:

· Improving conditions which are aggravated by weight (such as osteoarthritis)

· Reducing desire to consume alcohol

· Improving fatty liver

· Reducing cholesterol/lipids

· Reducing risk of prediabetes advancing to diabetes

Possible side effects and risks include:

· Nausea, vomiting, diarrhea, heartburn

· Constipation

· Abdominal discomfort

· Injection site reaction – pain, bruising, bleeding, infection

· Fatigue

· Dizziness

Serious possible reactions include:

· Thyroid cancer risk

· Allergic reaction which could be severe

· Pancreatitis

· Kidney injury or aggravation of chronic kidney disease

· Ileus (bowel paralysis)

· Gallstones, cholecystitis

CONTRAINDICATIONS – DO NOT TAKE IF YOU HAVE:

· Current pregnancy or planning pregnancy

· Current breast feeding

· History of medullary thyroid carcinoma

· History of multiple endocrine neoplasia syndrome type2 (MEN2)

· Previous allergic reaction to tirzepatide or semaglutide